1. Scrip
  2. >>R&D
  3. >>Clinical Trials

MacroGenics Plunges On Prostate Cancer ADC Safety Concerns

 
• By Andrew McConaghie

A more than 70% stock slide shows that investors are concerned about three as-yet unexplained deaths in a Phase II study of the US firm’s lead candidate.

• Source: Shutterstock

MacroGenics has seen its share price plummet after Phase II results of its antibody-drug conjugate (ADC) showed a worsening safety profile in metastatic castration-resistant prostate cancer patients, including three as-yet unexplained deaths.

The company’s NASDAQ-listed stock has doubled over the past 12 months, thanks to red-hot investor interest in the ADC field, but the results saw it lose 75% of its value...

Key Takeaways

  • The company’s share price has doubled in 12 months because of ADC excitement – but has come down to earth with a bump...

More from Clinical Trials

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.